338 related articles for article (PubMed ID: 19029379)
1. Accelerated tumor growth in mice deficient in DNAM-1 receptor.
Iguchi-Manaka A; Kai H; Yamashita Y; Shibata K; Tahara-Hanaoka S; Honda S; Yasui T; Kikutani H; Shibuya K; Shibuya A
J Exp Med; 2008 Dec; 205(13):2959-64. PubMed ID: 19029379
[TBL] [Abstract][Full Text] [Related]
2. Increased CD112 expression in methylcholanthrene-induced tumors in CD155-deficient mice.
Nagumo Y; Iguchi-Manaka A; Yamashita-Kanemaru Y; Abe F; Bernhardt G; Shibuya A; Shibuya K
PLoS One; 2014; 9(11):e112415. PubMed ID: 25384044
[TBL] [Abstract][Full Text] [Related]
3. DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors.
Gilfillan S; Chan CJ; Cella M; Haynes NM; Rapaport AS; Boles KS; Andrews DM; Smyth MJ; Colonna M
J Exp Med; 2008 Dec; 205(13):2965-73. PubMed ID: 19029380
[TBL] [Abstract][Full Text] [Related]
4. Tumor-derived soluble CD155 inhibits DNAM-1-mediated antitumor activity of natural killer cells.
Okumura G; Iguchi-Manaka A; Murata R; Yamashita-Kanemaru Y; Shibuya A; Shibuya K
J Exp Med; 2020 Mar; 217(4):1. PubMed ID: 32040157
[TBL] [Abstract][Full Text] [Related]
5. Boosting Natural Killer Cell-Mediated Targeting of Sarcoma Through DNAM-1 and NKG2D.
Sayitoglu EC; Georgoudaki AM; Chrobok M; Ozkazanc D; Josey BJ; Arif M; Kusser K; Hartman M; Chinn TM; Potens R; Pamukcu C; Krueger R; Zhang C; Mardinoglu A; Alici E; Temple HT; Sutlu T; Duru AD
Front Immunol; 2020; 11():40. PubMed ID: 32082316
[TBL] [Abstract][Full Text] [Related]
6. A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas.
Crowe NY; Smyth MJ; Godfrey DI
J Exp Med; 2002 Jul; 196(1):119-27. PubMed ID: 12093876
[TBL] [Abstract][Full Text] [Related]
7. DNAM-1 promotes inflammation-driven tumor development via enhancing IFN-γ production.
Nakamura-Shinya Y; Iguchi-Manaka A; Murata R; Sato K; Vo AV; Kanemaru K; Shibuya A; Shibuya K
Int Immunol; 2022 Feb; 34(3):149-157. PubMed ID: 34672321
[TBL] [Abstract][Full Text] [Related]
8. Development and Characterization of Novel Monoclonal Antibodies Against Human DNAM-1.
Okumura G; Abe F; Hirochika R; Shibuya A; Shibuya K
Monoclon Antib Immunodiagn Immunother; 2017 Jun; 36(3):135-139. PubMed ID: 28498033
[TBL] [Abstract][Full Text] [Related]
9. DNAM-1/CD155 interactions promote cytokine and NK cell-mediated suppression of poorly immunogenic melanoma metastases.
Chan CJ; Andrews DM; McLaughlin NM; Yagita H; Gilfillan S; Colonna M; Smyth MJ
J Immunol; 2010 Jan; 184(2):902-11. PubMed ID: 20008292
[TBL] [Abstract][Full Text] [Related]
10. Primary human tumor cells expressing CD155 impair tumor targeting by down-regulating DNAM-1 on NK cells.
Carlsten M; Norell H; Bryceson YT; Poschke I; Schedvins K; Ljunggren HG; Kiessling R; Malmberg KJ
J Immunol; 2009 Oct; 183(8):4921-30. PubMed ID: 19801517
[TBL] [Abstract][Full Text] [Related]
11. Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity.
Pievani A; Borleri G; Pende D; Moretta L; Rambaldi A; Golay J; Introna M
Blood; 2011 Sep; 118(12):3301-10. PubMed ID: 21821703
[TBL] [Abstract][Full Text] [Related]
12. Establishment and characterization of a novel anti-DNAM-1 monoclonal antibody.
Yamashita Y; Abe F; Hirochika R; Tahara-Hanaoka S; Shibuya A; Shibuya K
Monoclon Antib Immunodiagn Immunother; 2013 Feb; 32(1):60-4. PubMed ID: 23600509
[TBL] [Abstract][Full Text] [Related]
13. DNAM-1 controls NK cell activation via an ITT-like motif.
Zhang Z; Wu N; Lu Y; Davidson D; Colonna M; Veillette A
J Exp Med; 2015 Nov; 212(12):2165-82. PubMed ID: 26552706
[TBL] [Abstract][Full Text] [Related]
14. Tumor immunoediting by NKp46.
Elboim M; Gazit R; Gur C; Ghadially H; Betser-Cohen G; Mandelboim O
J Immunol; 2010 May; 184(10):5637-44. PubMed ID: 20404273
[TBL] [Abstract][Full Text] [Related]
15. Decreased tumor surveillance in perforin-deficient mice.
van den Broek ME; Kägi D; Ossendorp F; Toes R; Vamvakas S; Lutz WK; Melief CJ; Zinkernagel RM; Hengartner H
J Exp Med; 1996 Nov; 184(5):1781-90. PubMed ID: 8920866
[TBL] [Abstract][Full Text] [Related]
16. Expression of CD226 is associated to but not required for NK cell education.
Wagner AK; Kadri N; Snäll J; Brodin P; Gilfillan S; Colonna M; Bernhardt G; Höglund P; Kärre K; Chambers BJ
Nat Commun; 2017 May; 8():15627. PubMed ID: 28561023
[TBL] [Abstract][Full Text] [Related]
17. Tumor rejection by the poliovirus receptor family ligands of the DNAM-1 (CD226) receptor.
Tahara-Hanaoka S; Shibuya K; Kai H; Miyamoto A; Morikawa Y; Ohkochi N; Honda S; Shibuya A
Blood; 2006 Feb; 107(4):1491-6. PubMed ID: 16249389
[TBL] [Abstract][Full Text] [Related]
18. Critical roles of co-activation receptor DNAX accessory molecule-1 in natural killer cell immunity.
Xiong P; Sang HW; Zhu M
Immunology; 2015 Nov; 146(3):369-78. PubMed ID: 26235210
[TBL] [Abstract][Full Text] [Related]
19. Human breast tumor cells induce self-tolerance mechanisms to avoid NKG2D-mediated and DNAM-mediated NK cell recognition.
Mamessier E; Sylvain A; Bertucci F; Castellano R; Finetti P; Houvenaeghel G; Charaffe-Jaufret E; Birnbaum D; Moretta A; Olive D
Cancer Res; 2011 Nov; 71(21):6621-32. PubMed ID: 21937679
[TBL] [Abstract][Full Text] [Related]
20. The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells.
El-Sherbiny YM; Meade JL; Holmes TD; McGonagle D; Mackie SL; Morgan AW; Cook G; Feyler S; Richards SJ; Davies FE; Morgan GJ; Cook GP
Cancer Res; 2007 Sep; 67(18):8444-9. PubMed ID: 17875681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
